Novo Nordisk A/S

NOVO-B.CO

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 26, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
biphasic insulin aspart 30	Phase 3	Diabetes	-
Placebo cagrilintide	Phase 3	Overweight	-
sulphonylurea	Phase 3	Diabetes	-
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)	Phase 3	Menopause	-
turoctocog alfa	Phase 3	Congenital Bleeding Disorder	-
sitagliptin	Phase 3	Diabetes	-
Placebo (liraglutide)	Phase 3	Overweight	-
Placebo (semaglutide 2.4 mg)	Phase 3	Obesity	-
metformin	Phase 3	Diabetes	-
Cagrilintide	Phase 3	Obesity	-
somatropin	Phase 3	Growth Disorder	-
insulin glargine	Phase 3	Diabetes	-
insulin degludec/liraglutide	Phase 3	Diabetes	-
semaglutide 2.4 mg	Phase 3	Obesity	-
insulin detemir	Phase 3	Diabetes	-
Oral semaglutide	Phase 3	Diabetes Mellitus, Type 2	-
insulin icodec	Phase 3	Diabetes Mellitus, Type 1	-
biphasic insulin aspart 70	Phase 3	Diabetes	-
Ziltivekimab B	Phase 3	Cardiovascular Risk	-
semaglutide	Phase 3	Diabetes	-
Faster-acting insulin aspart	Phase 3	Diabetes	-
placebo	Phase 3	Metabolism and Nutrition Disorder	-
Dulaglutide	Phase 3	Diabetes	-
NNC0365-3769 (Mim8) PPX	Phase 3	Haemophilia A	-
Nonacog beta pegol	Phase 3	Haemophilia B	-
liraglutide	Phase 3	Diabetes	-
Insulin aspart	Phase 3	Diabetes	-
insulin degludec	Phase 3	Diabetes	-
biphasic insulin aspart 50	Phase 3	Diabetes	-
insulin degludec/insulin aspart	Phase 3	Diabetes	-
turoctocog alfa pegol	Phase 3	Congenital Bleeding Disorder	-
Placebo (semaglutide)	Phase 3	Diabetes Mellitus, Type 2	-
Faster aspart	Phase 3	Diabetes Mellitus, Type 1	-
estradiol, 10 mcg	Phase 3	Menopause	-
biphasic insulin aspart	Phase 3	Diabetes	-
Liraglutide 3.0 mg	Phase 3	Metabolism and Nutrition Disorder	-
basal insulin	Phase 3	Diabetes	-
insulin NPH	Phase 3	Diabetes	-
Etavopivat A	Phase 3	Sickle Cell Disease	-
Concizumab	Phase 3	Haemophilia A Without Inhibitors	-
Ziltivekimab	Phase 2	Chronic Kidney Diseases	-
catridecacog	Phase 2	Acquired Bleeding Disorder	-
activated recombinant human factor VII	Phase 2	Other Haemostasis Disorder	-
eptacog alfa (activated)	Phase 2	Congenital Bleeding Disorder	-
NNC0114-0006	Phase 2	Inflammation	-
recombinant interleukin-21	Phase 2	Cancer	-
human insulin	Phase 2	Diabetes	-
NNC0519-0130	Phase 2	Obesity	-
activated recombinant human factor VII, long acting	Phase 2	Congenital Bleeding Disorder	-
CagriSema (Cagrilintide B and Semaglutide I)	Phase 2	Diabetes Mellitus, Type 2	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Ziltivekimab B Phase 3 Results Expected

Jun 26, 2026Ziltivekimab B

Primary completion for Ziltivekimab B trial (NCT05021835) in Cardiovascular Risk

Source

Phase 2

CagriSema (Cagrilintide B and Semaglutide I) Phase 2 Results Expected

Aug 21, 2026CagriSema (Cagrilintide B and Semaglutide I)

Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT06797869) in Diabetes Mellitus, Type 2

Source

Regulatory Approvals

NOVO-B.CO News

Novo Nordisk A/S

NOVO-B.CO

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Jun 26, 2026

Drug Pipeline

Drug Name	Phase	Indication	Designations
biphasic insulin aspart 30	Phase 3	Diabetes	-
Placebo cagrilintide	Phase 3	Overweight	-
sulphonylurea	Phase 3	Diabetes	-
0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)	Phase 3	Menopause	-
turoctocog alfa	Phase 3	Congenital Bleeding Disorder	-
sitagliptin	Phase 3	Diabetes	-
Placebo (liraglutide)	Phase 3	Overweight	-
Placebo (semaglutide 2.4 mg)	Phase 3	Obesity	-
metformin	Phase 3	Diabetes	-
Cagrilintide	Phase 3	Obesity	-
somatropin	Phase 3	Growth Disorder	-
insulin glargine	Phase 3	Diabetes	-
insulin degludec/liraglutide	Phase 3	Diabetes	-
semaglutide 2.4 mg	Phase 3	Obesity	-
insulin detemir	Phase 3	Diabetes	-
Oral semaglutide	Phase 3	Diabetes Mellitus, Type 2	-
insulin icodec	Phase 3	Diabetes Mellitus, Type 1	-
biphasic insulin aspart 70	Phase 3	Diabetes	-
Ziltivekimab B	Phase 3	Cardiovascular Risk	-
semaglutide	Phase 3	Diabetes	-
Faster-acting insulin aspart	Phase 3	Diabetes	-
placebo	Phase 3	Metabolism and Nutrition Disorder	-
Dulaglutide	Phase 3	Diabetes	-
NNC0365-3769 (Mim8) PPX	Phase 3	Haemophilia A	-
Nonacog beta pegol	Phase 3	Haemophilia B	-
liraglutide	Phase 3	Diabetes	-
Insulin aspart	Phase 3	Diabetes	-
insulin degludec	Phase 3	Diabetes	-
biphasic insulin aspart 50	Phase 3	Diabetes	-
insulin degludec/insulin aspart	Phase 3	Diabetes	-
turoctocog alfa pegol	Phase 3	Congenital Bleeding Disorder	-
Placebo (semaglutide)	Phase 3	Diabetes Mellitus, Type 2	-
Faster aspart	Phase 3	Diabetes Mellitus, Type 1	-
estradiol, 10 mcg	Phase 3	Menopause	-
biphasic insulin aspart	Phase 3	Diabetes	-
Liraglutide 3.0 mg	Phase 3	Metabolism and Nutrition Disorder	-
basal insulin	Phase 3	Diabetes	-
insulin NPH	Phase 3	Diabetes	-
Etavopivat A	Phase 3	Sickle Cell Disease	-
Concizumab	Phase 3	Haemophilia A Without Inhibitors	-
Ziltivekimab	Phase 2	Chronic Kidney Diseases	-
catridecacog	Phase 2	Acquired Bleeding Disorder	-
activated recombinant human factor VII	Phase 2	Other Haemostasis Disorder	-
eptacog alfa (activated)	Phase 2	Congenital Bleeding Disorder	-
NNC0114-0006	Phase 2	Inflammation	-
recombinant interleukin-21	Phase 2	Cancer	-
human insulin	Phase 2	Diabetes	-
NNC0519-0130	Phase 2	Obesity	-
activated recombinant human factor VII, long acting	Phase 2	Congenital Bleeding Disorder	-
CagriSema (Cagrilintide B and Semaglutide I)	Phase 2	Diabetes Mellitus, Type 2	-

Catalyst Timeline

2 upcoming, 0 past

⭐Phase 3Next

Ziltivekimab B Phase 3 Results Expected

Jun 26, 2026Ziltivekimab B

Primary completion for Ziltivekimab B trial (NCT05021835) in Cardiovascular Risk

Source

Phase 2

CagriSema (Cagrilintide B and Semaglutide I) Phase 2 Results Expected

Aug 21, 2026CagriSema (Cagrilintide B and Semaglutide I)

Primary completion for CagriSema (Cagrilintide B and Semaglutide I) trial (NCT06797869) in Diabetes Mellitus, Type 2

Source

Regulatory Approvals

NOVO-B.CO News